Compare BCYC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | EBS |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 411.1M |
| IPO Year | 2019 | 2006 |
| Metric | BCYC | EBS |
|---|---|---|
| Price | $4.84 | $8.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $13.90 | $12.00 |
| AVG Volume (30 Days) | 422.2K | ★ 638.8K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.93 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.24 | $4.71 |
| 52 Week High | $9.55 | $14.06 |
| Indicator | BCYC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 43.26 |
| Support Level | $4.24 | $7.73 |
| Resistance Level | $5.41 | $8.54 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 15.04 | 21.09 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.